Janus Henderson Group
SYRE icon

Janus Henderson Group’s Spyre Therapeutics SYRE Stock Holding History

Janus Henderson Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.6M Sell
1,656,164
-172,845
-9% -$6.52M 0.04% 312
2025
Q4 		$59.9M Buy
1,829,009
+1,816,009
+13,969% +$47.5M 0.03% 380
2025
Q3 		$218K Hold
13,000
– – ﹤0.01% 2312
2025
Q2 		$194K Sell
13,000
-1,028,410
-99% -$15.2M ﹤0.01% 2323
2025
Q1 		$18.7M Sell
1,041,410
-415,330
-29% -$8.64M 0.01% 581
2024
Q4 		$33.9M Buy
1,456,740
+336,209
+30% +$9.86M 0.02% 473
2024
Q3 		$32.9M Buy
1,120,531
+446,664
+66% +$12.4M 0.02% 475
2024
Q2 		$15.9M Buy
673,867
+659,890
+4,721% +$22.3M 0.01% 611
2024
Q1 		$530K Buy
+13,977
New +$405K ﹤0.01% 1980

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group's SYRE Position: Q1 2026 in Review

Janus Henderson Group reduced its Spyre Therapeutics (SYRE) stake by 9.5% in Q1 2026, selling an estimated $6.52M and leaving 1,656,164 shares worth $83.6M. The position accounts for 0.04% of the portfolio, ranked #312.

Janus Henderson Group first reported a position in SYRE in Q1 2024 and has held it in 9 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Janus Henderson Group held 1,656,164 shares of Spyre Therapeutics worth $83.6M as of Q1 2026.
  • Janus Henderson Group sold 172,845 Spyre Therapeutics shares in Q1 2026, an estimated $6.52M.
  • Spyre Therapeutics made up 0.04% of Janus Henderson Group's portfolio in Q1 2026, its #312 holding.
  • Janus Henderson Group first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.